inositol has been researched along with Encephalopathy, Hepatic in 44 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to investigate the effects of ammonia and manganese in the metabolism of minimal hepatic encephalopathy (MHE)." | 8.31 | The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study. ( Li, Y; Liu, XF; Lu, JJ; Qiang, JW; Yang, XY, 2023) |
| "Myo-inositol and glutamine levels in the brain were studied in vivo by 1H-MR spectroscopy in patients with hypo-osmolarity and hepatic encephalopathy." | 7.69 | Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. ( Bayer, S; Ernst, T; Gerok, W; Häussinger, D; Hennig, J; Langer, M; Laubenberger, J; vom Dahl, S, 1994) |
| "Cerebral myo-inositol depletion is found in patients with hepatic encephalopathy and can be implicated in the pathogenesis of hepatic encephalopathy." | 7.69 | Scyllo-inositol depletion in hepatic encephalopathy. ( Lien, YH; Michaelis, T; Moats, RA; Ross, BD, 1994) |
| " An osmoregulatory response to the increase in brain glutamine may explain the decrease in brain myo-inositol; if this is the case, organic osmolytes may account for differences in the development of brain edema seen in acute or chronic liver failure." | 7.69 | Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. ( Blei, AT; Cordoba, J; Gottstein, J, 1996) |
| "In a double-blind study, overt hepatic encephalopathy (HE) and SCHE (defined with clinical and neuropsychiatric tests) were compared by means of H-1 MR spectroscopic criteria--reduction in cerebral myo-inositol (< 2 standard deviations [SDs] from normal) and choline (< 2 SDs from normal) with or without increased cerebral glutamine (> 1 SD from normal)--in 20 patients with cirrhosis." | 5.07 | Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. ( Ernst, T; Jacobson, S; Korula, J; Kreis, R; Moats, RA; Ross, BD; Shonk, T; Villamil, F, 1994) |
| "This study was to investigate the effects of ammonia and manganese in the metabolism of minimal hepatic encephalopathy (MHE)." | 4.31 | The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study. ( Li, Y; Liu, XF; Lu, JJ; Qiang, JW; Yang, XY, 2023) |
| "In hepatic encephalopathy (HE), osmotic stressors promoting brain edema result in a compensatory drop in the astrocyte metabolite myo-inositol (mI)." | 3.96 | Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis. ( Cole, S; Csete, M; King, KS; Mena, E; Tran, TT; Wei, K, 2020) |
| "Compared with control dogs, dogs with hepatic encephalopathy had specific changes, which included significantly higher concentration relative to water of the glutamine-glutamate complex and significantly lower concentration of myoinositol." | 3.80 | In vivo proton magnetic resonance spectroscopy for the evaluation of hepatic encephalopathy in dogs. ( Beckman, K; Carrera, I; Dennler, M; Kircher, PR; Meier, D; Richter, H, 2014) |
| "Asymmetric dimethylarginine (ADMA) is an inhibitor of nitric oxide synthase that accumulates in liver disease and may contribute to hepatic encephalopathy (HE)." | 3.79 | Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. ( Ahluwalia, V; Bajaj, JS; Bouneva, I; Fuchs, M; Gilles, H; Heuman, DM; Kraft, KA; Luketic, V; Monteith, P; Noble, NA; Puri, P; Sanyal, AJ; Sterling, RK; Stravitz, RT; Wade, JB; White, MB, 2013) |
| " Significant decrease of myo-inositol in adults is probably due to cellular osmoregulation secondary to long-standing hyperammonemia." | 3.76 | Brain MR imaging and 1H-MR spectroscopy changes in patients with extrahepatic portal vein obstruction from early childhood to adulthood. ( Gupta, RK; Rathore, RK; Saksena, S; Saraswat, VA; Srivastava, A; Thomas, MA; Yadav, SK, 2010) |
| " Decreased myo-inositol and increased glutamine levels were noted to be the most sensitive spectroscopic markers for cirrhotic patients with hepatic encephalopathy (HE)." | 3.70 | Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. ( Kim, ST; Lee, JH; Lee, YS; Lim, TH; Min, YI; Mun, CW; Seo, DW; Suh, DJ, 1999) |
| "Myo-inositol and glutamine levels in the brain were studied in vivo by 1H-MR spectroscopy in patients with hypo-osmolarity and hepatic encephalopathy." | 3.69 | Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. ( Bayer, S; Ernst, T; Gerok, W; Häussinger, D; Hennig, J; Langer, M; Laubenberger, J; vom Dahl, S, 1994) |
| "Cerebral myo-inositol depletion is found in patients with hepatic encephalopathy and can be implicated in the pathogenesis of hepatic encephalopathy." | 3.69 | Scyllo-inositol depletion in hepatic encephalopathy. ( Lien, YH; Michaelis, T; Moats, RA; Ross, BD, 1994) |
| " An osmoregulatory response to the increase in brain glutamine may explain the decrease in brain myo-inositol; if this is the case, organic osmolytes may account for differences in the development of brain edema seen in acute or chronic liver failure." | 3.69 | Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. ( Blei, AT; Cordoba, J; Gottstein, J, 1996) |
| "Rats with portacaval shunts and humans with hepatic encephalopathy show severe myo-inositol depletion in the brain." | 3.68 | Decrease in cerebral inositols in rats and humans. ( Filippi, D; Lien, YH; Moats, RA; Ross, BD, 1993) |
| "Minimal hepatic encephalopathy (MHE) is diagnosed when hepatic patients perform worse on psychometric tests compared to healthy controls." | 2.78 | Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. ( El Yamany, SA; Hamisa, MF; Hasan, AM; Soliman, HH; Ziada, DH, 2013) |
| "Human hepatic encephalopathy (HE) is identified by a new noninvasive test, proton magnetic resonance spectroscopy (1H MRS) applied to the brain in a few minutes." | 2.39 | Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? ( Blüml, S; Danielsen, ER; Ross, BD, 1996) |
| "In patients with hepatic encephalopathy, GABA+ levels in the cerebello-thalamo-cortical loop are significantly increased in the cerebellum and significantly decreased in the motor cortex." | 1.91 | J-difference GABA-edited MRS reveals altered cerebello-thalamo-cortical metabolism in patients with hepatic encephalopathy. ( Ahn, S; Butz, M; Füllenbach, ND; Häussinger, D; Jördens, MS; Ljimani, A; Oeltzschner, G; Schnitzler, A; Thiel, TA; Wilms, LM; Wittsack, HJ; Zöllner, HJ, 2023) |
| "The pathogenesis of hepatic encephalopathy (HE) is not fully understood yet." | 1.42 | Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes. ( Baumgarten, TJ; Butz, M; Hoogenboom, N; Oeltzschner, G; Schnitzler, A; Wittsack, HJ, 2015) |
| "Hyponatremia (HN) and hepatic encephalopathy (HE) together can impair health-related quality of life (HRQOL) and cognition in cirrhosis." | 1.39 | Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. ( Ahluwalia, V; Bajaj, JS; Bouneva, I; Fuchs, M; Gilles, H; Heuman, DM; Kraft, KA; Luketic, V; Puri, P; Sanyal, AJ; Sterling, RK; Stravitz, RT; Thacker, L; Wade, JB, 2013) |
| "Acute-on-chronic liver failure (ACLF), acute liver failure (ALF) and chronic liver disease (CLD) are common forms of liver failure and present with similar clinical profiles." | 1.35 | In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure. ( Gupta, RK; Nath, K; Radha Krishna, Y; Saraswat, VA; Thomas, MA; Verma, A, 2008) |
| "Minimal hepatic encephalopathy (MHE) is frequently diagnosed in patients with liver cirrhosis who do not show overt clinical cirrhosis-associated neurological deficits." | 1.33 | Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy. ( Graziadei, IW; Hinterhuber, H; Kugener, A; Marksteiner, J; Mattedi, M; Mechtcheriakov, S; Schocke, M; Vogel, W, 2005) |
| "6 patients with liver cirrhosis were included in this pilot study." | 1.33 | [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)]. ( Gregor, M; Hass, HG; Hösl, F; Kaiser, S; Nägele, T; Seeger, U, 2005) |
| "Myo-inositol levels were strongly decreased already at 3h after treatment with NH4Cl; other intracellular osmolytes, such as hypotaurine and choline-containing compounds were also decreased, along with a concomitant increase of both the total concentration and the amount of newly synthesized glutamine, alanine, and glutathione." | 1.33 | Ammonia toxicity under hyponatremic conditions in astrocytes: de novo synthesis of amino acids for the osmoregulatory response. ( Leibfritz, D; Zwingmann, C, 2005) |
| "Episodic hepatic encephalopathy has been described in patients with portal vein thrombosis, but it is not known if these patients develop minimal hepatic encephalopathy." | 1.33 | Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. ( Alonso, J; Bosch, J; Córdoba, J; García-Pagán, JC; Mínguez, B; Rovira, A; Turnes, J, 2006) |
| "Six patients, who underwent TIPS for treatment of portal hypertension, were examined by MRS I week before and 1 week after TIPS." | 1.31 | Proton MR spectroscopy of the brain in patients treated with TIPS. ( Hamuro, M; Higashida, M; Kaminou, T; Matsuoka, T; Nakamura, K; Yamada, R, 2000) |
| "Hepatic encephalopathy is a common problem in cirrhosis." | 1.30 | Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. ( Andus, T; Feuerbach, S; Fründ, R; Geissler, A; Held, P; Hollerbach, S; Holstege, A; Lock, G; Schölmerich, J, 1997) |
| "Also, patients with Wilson disease and portosystemic shunting had lower myo-inositol-creatine ratios than did patients with Wilson disease and no portosystemic shunting (P < ." | 1.30 | Differentiation between portal-systemic encephalopathy and neurodegenerative disorders in patients with Wilson disease: H-1 MR spectroscopy. ( Hoogenraad, TU; Mali, WP; Van Den Heuvel, AG; Van der Grond, J; Van Rooij, LG; Van Wassenaer-van Hall, HN, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (40.91) | 18.2507 |
| 2000's | 10 (22.73) | 29.6817 |
| 2010's | 11 (25.00) | 24.3611 |
| 2020's | 5 (11.36) | 2.80 |
| Authors | Studies |
|---|---|
| Zöllner, HJ | 1 |
| Thiel, TA | 1 |
| Füllenbach, ND | 1 |
| Jördens, MS | 1 |
| Ahn, S | 1 |
| Wilms, LM | 1 |
| Ljimani, A | 1 |
| Häussinger, D | 2 |
| Butz, M | 2 |
| Wittsack, HJ | 2 |
| Schnitzler, A | 2 |
| Oeltzschner, G | 2 |
| Chaganti, J | 1 |
| Zeng, G | 1 |
| Tun, N | 1 |
| Lockart, I | 1 |
| Abdelshaheed, C | 1 |
| Cysique, L | 1 |
| Montagnese, S | 1 |
| Brew, BJ | 1 |
| Danta, M | 1 |
| Liu, XF | 1 |
| Lu, JJ | 1 |
| Li, Y | 1 |
| Yang, XY | 1 |
| Qiang, JW | 1 |
| Tran, TT | 1 |
| Wei, K | 1 |
| Cole, S | 1 |
| Mena, E | 1 |
| Csete, M | 1 |
| King, KS | 1 |
| Asaki, Y | 1 |
| Murofushi, Y | 1 |
| Yasukawa, K | 1 |
| Hara, M | 1 |
| Takanashi, JI | 1 |
| Ciarlariello, VB | 1 |
| Fujino, MVT | 1 |
| Almeida, MD | 1 |
| Barsottini, OGP | 1 |
| Pedroso, JL | 1 |
| Ahluwalia, V | 2 |
| Wade, JB | 2 |
| Thacker, L | 1 |
| Kraft, KA | 2 |
| Sterling, RK | 2 |
| Stravitz, RT | 2 |
| Fuchs, M | 2 |
| Bouneva, I | 2 |
| Puri, P | 2 |
| Luketic, V | 2 |
| Sanyal, AJ | 2 |
| Gilles, H | 2 |
| Heuman, DM | 2 |
| Bajaj, JS | 2 |
| Ziada, DH | 1 |
| Soliman, HH | 1 |
| El Yamany, SA | 1 |
| Hamisa, MF | 1 |
| Hasan, AM | 1 |
| Razek, AA | 1 |
| Abdalla, A | 1 |
| Ezzat, A | 1 |
| Megahed, A | 1 |
| Barakat, T | 1 |
| Carrera, I | 1 |
| Kircher, PR | 1 |
| Meier, D | 1 |
| Richter, H | 1 |
| Beckman, K | 1 |
| Dennler, M | 1 |
| Meng, LP | 1 |
| Chen, YC | 1 |
| Li, YH | 1 |
| Zhu, JS | 1 |
| Ye, JL | 1 |
| Baumgarten, TJ | 1 |
| Hoogenboom, N | 1 |
| Singhal, A | 1 |
| Nagarajan, R | 1 |
| Kumar, R | 1 |
| Huda, A | 1 |
| Gupta, RK | 5 |
| Thomas, MA | 4 |
| Yadav, SK | 1 |
| Saksena, S | 2 |
| Srivastava, A | 2 |
| Saraswat, VA | 4 |
| Rathore, RK | 1 |
| Herman-Sucharska, I | 1 |
| Grzybek, M | 1 |
| Grochowska, A | 1 |
| Karcz, P | 1 |
| Urbanik, A | 1 |
| Bokemeyer, M | 1 |
| Ding, XQ | 1 |
| Goldbecker, A | 1 |
| Raab, P | 1 |
| Heeren, M | 1 |
| Arvanitis, D | 1 |
| Tillmann, HL | 1 |
| Lanfermann, H | 1 |
| Weissenborn, K | 1 |
| White, MB | 1 |
| Noble, NA | 1 |
| Monteith, P | 1 |
| Zwingmann, C | 2 |
| Chatauret, N | 1 |
| Rose, C | 1 |
| Leibfritz, D | 2 |
| Butterworth, RF | 1 |
| Mechtcheriakov, S | 1 |
| Schocke, M | 1 |
| Kugener, A | 1 |
| Graziadei, IW | 1 |
| Mattedi, M | 1 |
| Hinterhuber, H | 1 |
| Vogel, W | 1 |
| Marksteiner, J | 1 |
| Hass, HG | 1 |
| Nägele, T | 1 |
| Seeger, U | 2 |
| Hösl, F | 1 |
| Gregor, M | 2 |
| Kaiser, S | 2 |
| Mínguez, B | 1 |
| García-Pagán, JC | 1 |
| Bosch, J | 1 |
| Turnes, J | 1 |
| Alonso, J | 1 |
| Rovira, A | 1 |
| Córdoba, J | 3 |
| Rai, V | 1 |
| Rathore, RS | 1 |
| Purwar, A | 1 |
| Kumar, M | 1 |
| Verma, A | 1 |
| Radha Krishna, Y | 1 |
| Nath, K | 1 |
| Norenberg, MD | 1 |
| Bender, AS | 1 |
| Danielsen, ER | 2 |
| Michaelis, T | 2 |
| Ross, BD | 8 |
| Laubenberger, J | 2 |
| vom Dahl, S | 1 |
| Ernst, T | 2 |
| Bayer, S | 2 |
| Langer, M | 2 |
| Gerok, W | 1 |
| Hennig, J | 2 |
| Jacobson, S | 1 |
| Villamil, F | 1 |
| Korula, J | 1 |
| Kreis, R | 4 |
| Shonk, T | 1 |
| Moats, RA | 3 |
| Lien, YH | 2 |
| Filippi, D | 1 |
| Poptani, H | 1 |
| Dhiman, RK | 1 |
| Kohli, A | 1 |
| Gujral, RB | 1 |
| Naik, SR | 1 |
| Gottstein, J | 1 |
| Blei, AT | 1 |
| Blüml, S | 1 |
| Geissler, A | 1 |
| Lock, G | 1 |
| Fründ, R | 1 |
| Held, P | 1 |
| Hollerbach, S | 1 |
| Andus, T | 1 |
| Schölmerich, J | 1 |
| Feuerbach, S | 1 |
| Holstege, A | 1 |
| Van Den Heuvel, AG | 1 |
| Van der Grond, J | 1 |
| Van Rooij, LG | 1 |
| Van Wassenaer-van Hall, HN | 1 |
| Hoogenraad, TU | 1 |
| Mali, WP | 1 |
| Thiel, T | 1 |
| Gruetter, R | 1 |
| Weisdorf, SA | 1 |
| Rajanayagan, V | 1 |
| Terpstra, M | 1 |
| Merkle, H | 1 |
| Truwit, CL | 1 |
| Garwood, M | 1 |
| Nyberg, SL | 1 |
| Uğurbil, K | 1 |
| Lee, JH | 1 |
| Seo, DW | 1 |
| Lee, YS | 1 |
| Kim, ST | 1 |
| Mun, CW | 1 |
| Lim, TH | 1 |
| Min, YI | 1 |
| Suh, DJ | 1 |
| Naegele, T | 1 |
| Grodd, W | 1 |
| Viebahn, R | 1 |
| Klose, U | 1 |
| Seitz, D | 1 |
| Mader, I | 1 |
| Mayer, J | 1 |
| Lauchart, W | 1 |
| Voigt, K | 1 |
| Hamuro, M | 1 |
| Nakamura, K | 1 |
| Matsuoka, T | 1 |
| Kaminou, T | 1 |
| Higashida, M | 1 |
| Yamada, R | 1 |
| Farrow, NA | 1 |
| Ackerman, Z | 1 |
| Farrow, N | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Magnetic Resonance Imaging in Detection of Minimal Hepatic Encephalopathy[NCT04131205] | 40 participants (Anticipated) | Observational | 2019-06-01 | Recruiting | |||
| A Magnetic Resonance Spectroscopy Study of Neuropsychiatric Effects Associated With Cytokines[NCT00001547] | 150 participants | Observational | 1996-06-30 | Completed | |||
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
1 review available for inositol and Encephalopathy, Hepatic
| Article | Year |
|---|---|
Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy?
Topics: Animals; Astrocytes; Brain; Choline; Cognition Disorders; Disease Models, Animal; Glutamine; Hepatic | 1996 |
3 trials available for inositol and Encephalopathy, Hepatic
| Article | Year |
|---|---|
Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
Topics: Adult; Ammonia; Brain; Choline; Creatinine; Female; Gastrointestinal Agents; Gastrointestinal Tract; | 2013 |
Minimal hepatic encephalopathy in children with liver cirrhosis: diffusion-weighted MR imaging and proton MR spectroscopy of the brain.
Topics: Adolescent; Child; Choline; Creatine; Diffusion Magnetic Resonance Imaging; Female; Glutamic Acid; H | 2014 |
Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities.
Topics: Adult; Brain Chemistry; Choline; Double-Blind Method; Female; Glutamine; Hepatic Encephalopathy; Hum | 1994 |
40 other studies available for inositol and Encephalopathy, Hepatic
| Article | Year |
|---|---|
J-difference GABA-edited MRS reveals altered cerebello-thalamo-cortical metabolism in patients with hepatic encephalopathy.
Topics: Ammonia; Cerebellum; Choline; gamma-Aminobutyric Acid; Glutamine; Hepatic Encephalopathy; Humans; In | 2023 |
Novel magnetic resonance KTRANS measurement of blood-brain barrier permeability correlated with covert HE.
Topics: Blood-Brain Barrier; Brain; Choline; Glutamine; Hepatic Encephalopathy; Humans; Inositol; Liver Cirr | 2023 |
The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: A comparison metabolomics study.
Topics: Alanine; Ammonia; Animals; Arginine; Brain; Citrulline; gamma-Aminobutyric Acid; Glutamic Acid; Glut | 2023 |
Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.
Topics: Aged; Biomarkers; Brain; Brain Edema; Female; Glutamine; Hepatic Encephalopathy; Humans; Inositol; M | 2020 |
Neurochemistry of hyponatremic encephalopathy evaluated by MR spectroscopy.
Topics: Aspartic Acid; Child; Creatine; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Hyponatrem | 2020 |
Teaching Video NeuroImages: Hepatic myelopathy: An unusual neurologic complication of hepatic encephalopathy.
Topics: Choline; Gait Disorders, Neurologic; Globus Pallidus; Glutamic Acid; Glutamine; Hepatic Encephalopat | 2019 |
Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.
Topics: Brain; Cognition; Cognition Disorders; Diuretics; Female; Glutamic Acid; Glutamine; Hepatic Encephal | 2013 |
In vivo proton magnetic resonance spectroscopy for the evaluation of hepatic encephalopathy in dogs.
Topics: Animals; Brain; Case-Control Studies; Dog Diseases; Dogs; Female; Glutamic Acid; Glutamine; Hepatic | 2014 |
Viability assessment of magnetic resonance spectroscopy for the detection of minimal hepatic encephalopathy severity.
Topics: Adult; Aspartic Acid; Basal Ganglia; Brain; Cognition; Creatine; Female; Glutamic Acid; Glutamine; G | 2015 |
Low visual cortex GABA levels in hepatic encephalopathy: links to blood ammonia, critical flicker frequency, and brain osmolytes.
Topics: Ammonia; Brain Chemistry; Creatine; Female; Flicker Fusion; gamma-Aminobutyric Acid; Glutamine; Glyc | 2015 |
Magnetic resonance T2-relaxometry and 2D L-correlated spectroscopy in patients with minimal hepatic encephalopathy.
Topics: Adult; Aged; Brain; Choline; Creatine; Female; Hepatic Encephalopathy; Humans; Inositol; Liver; Magn | 2009 |
Brain MR imaging and 1H-MR spectroscopy changes in patients with extrahepatic portal vein obstruction from early childhood to adulthood.
Topics: Adolescent; Adult; Age Factors; Ammonia; Basal Ganglia; Child; Female; Hepatic Encephalopathy; Human | 2010 |
[Myoinositol trends in HMRS brain spectrum of patients with hepatic encephalopathy].
Topics: Ammonia; Biomarkers; Choline; Creatine; Hepatic Encephalopathy; Humans; Inositol; Liver; Magnetic Re | 2010 |
Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy.
Topics: Adult; Aged; Aspartic Acid; Brain; Brain Mapping; Case-Control Studies; Choline; Cognition Disorders | 2011 |
Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.
Topics: Adult; Arginine; Aspartic Acid; Biomarkers; Brain; Cognition Disorders; Cross-Sectional Studies; Fem | 2013 |
Selective alterations of brain osmolytes in acute liver failure: protective effect of mild hypothermia.
Topics: Animals; Brain Edema; Disease Models, Animal; Glutamine; Hepatic Encephalopathy; Hypothermia, Induce | 2004 |
Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy.
Topics: Aspartic Acid; Cerebral Cortex; Choline; Creatinine; Female; Glutamic Acid; Glutamine; Gyrus Cinguli | 2005 |
[Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Topics: Adult; Ammonia; Brain; Choline; Combined Modality Therapy; Creatinine; Diet, Protein-Restricted; Dip | 2005 |
Ammonia toxicity under hyponatremic conditions in astrocytes: de novo synthesis of amino acids for the osmoregulatory response.
Topics: Alanine; Amino Acids; Ammonia; Ammonium Chloride; Animals; Animals, Newborn; Astrocytes; Brain Edema | 2005 |
Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy.
Topics: Administration, Oral; Adult; Ammonia; Attention; Body Water; Brain; Case-Control Studies; Female; Gl | 2006 |
Cerebral diffusion tensor imaging and in vivo proton magnetic resonance spectroscopy in patients with fulminant hepatic failure.
Topics: Adolescent; Adult; Anisotropy; Aspartic Acid; Biomarkers; Case-Control Studies; Cerebrovascular Circ | 2008 |
In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Brain; Case-Control Studies; Choline; Chronic Disease; Creat | 2008 |
Astrocyte swelling in liver failure: role of glutamine and benzodiazepines.
Topics: Ammonia; Animals; Animals, Newborn; Astrocytes; Brain Edema; Cells, Cultured; Cerebral Cortex; Chlor | 1994 |
Three methods of calibration in quantitative proton MR spectroscopy.
Topics: Adult; Aspartic Acid; Body Water; Brain; Brain Chemistry; Brain Injuries; Calibration; Choline; Crea | 1995 |
Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Brain Chemistry; Brain Diseases; Female; Glutamine; | 1994 |
Scyllo-inositol depletion in hepatic encephalopathy.
Topics: Autopsy; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Hepatic Encephalopathy; Human | 1994 |
Decrease in cerebral inositols in rats and humans.
Topics: Animals; Brain Chemistry; Disease Models, Animal; Hepatic Encephalopathy; Humans; Inositol; Magnetic | 1993 |
Magnetic resonance imaging and localized in vivo proton spectroscopy in patients with fulminant hepatic failure.
Topics: Adult; Atrophy; Brain; Cerebral Cortex; Female; Glutamine; Hepatic Encephalopathy; Humans; Inositol; | 1993 |
Glutamine, myo-inositol, and brain edema in acute liver failure.
Topics: Brain; Brain Edema; Glutamine; Hepatic Encephalopathy; Humans; Inositol | 1996 |
Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema.
Topics: Ammonia; Animals; Blood Pressure; Body Water; Body Weight; Brain; Brain Edema; Cerebral Cortex; Glut | 1996 |
Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging.
Topics: Adult; Aged; Aspartic Acid; Brain; Choline; Female; Glutamic Acid; Hepatic Encephalopathy; Humans; I | 1997 |
Differentiation between portal-systemic encephalopathy and neurodegenerative disorders in patients with Wilson disease: H-1 MR spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Brain; Brain Diseases; Choline; Creatinine; Diagnosis, Differential; Fem | 1997 |
[Clinical uses of proton magnetic resonance spectroscopy of the brain].
Topics: AIDS Dementia Complex; Alzheimer Disease; Animals; Aspartic Acid; Brain; Brain Diseases; Brain Disea | 1998 |
Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength.
Topics: Adult; Amino Acids; Animals; Brain Chemistry; Dogs; Hepatic Encephalopathy; Humans; Image Processing | 1998 |
Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve.
Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Brain; Choline; Creatinine; Energy Metabolism; Female; Gl | 1999 |
MR imaging and (1)H spectroscopy of brain metabolites in hepatic encephalopathy: time-course of renormalization after liver transplantation.
Topics: Adult; Basal Ganglia; Choline; Creatine; Energy Metabolism; Female; Glutamic Acid; Glutamine; Hepati | 2000 |
Proton MR spectroscopy of the brain in patients treated with TIPS.
Topics: Adult; Aged; Brain Chemistry; Female; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Hype | 2000 |
Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy.
Topics: Aspartic Acid; Brain; Choline; Female; Glucose; Glutamates; Glutamic Acid; Glutamine; Hepatic Enceph | 1992 |
Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols.
Topics: Aged; Brain; Choline; Chronic Disease; Data Interpretation, Statistical; Electronic Data Processing; | 1991 |
Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy.
Topics: Aged; Female; Glutamine; Hepatic Encephalopathy; Humans; Inositol; Magnetic Resonance Spectroscopy; | 1990 |